DOCSLIB.ORG

Enzymes from Higher Eukaryotes for Industrial Biocatalysis, Food Technol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enzymes from Higher Eukaryotes for Industrial Biocatalysis, Food Technol Z. LIU et al.: Enzymes from Higher Eukaryotes for Industrial Biocatalysis, Food Technol. Biotechnol. 42 (4) 237–249 (2004) 237 UDC 577.128.15 ISSN 1330-9862 review (FTB-1420) Enzymes from Higher Eukaryotes for Industrial Biocatalysis Zhibin Liu1, Roland Weis1 and Anton Glieder2* 1Research Centre Applied Biocatalysis, Petersgasse 14, A-8010 Graz, Austria 2Institute of Molecular Biotechnology, Petersgasse 14, A-8010 Graz, Austria Received: August 6, 2004 Revised version: September 9, 2004 Accepted: November 22, 2004 Summary The industrial production of fine chemicals, feed and food ingredients, pharmaceuti- cals, agrochemicals and their respective intermediates relies on an increasing application of biocatalysis, i.e. on enzyme or whole-cell catalyzed conversions of molecules. Simple procedures for discovery, cloning and over-expression as well as fast growth favour fungi, yeasts and especially bacteria as sources of biocatalysts. Higher eukaryotes also harbour an almost unlimited number of potential biocatalysts, although to date the limited supply of enzymes, the high heterogeneity of enzyme preparations and the hazard of infectious contaminants keep some interesting candidates out of reach for industrial bioprocesses. In the past only a few animal and plant enzymes from agricultural waste materials were em- ployed in food processing. The use of bacterial expression strains or non-conventional yeasts for the heterologous production of efficient eukaryotic enzymes can overcome the bottleneck in enzyme supply and provide sufficient amounts of homogenous enzyme pre- parations for reliable and economically feasible applications at large scale. Ideal enzymatic processes represent an environmentally friendly, »near-to-completion« conversion of (mostly non-natural) substrates to pure products. Recent developments demonstrate the commer- cial feasibility of large-scale biocatalytic processes employing enzymes from higher eu- karyotes (e.g. plants, animals) and also their usefulness in some small-scale industrial ap- plications. Key words: enzymes, eukaryotes, industrial biocatalysis Introduction Microorganisms and their enzymes are widely ex- as well as commodity and agrochemicals (1–4). The pre- ploited in biocatalysis to produce a broad spectrum of ferred use of enzymes from bacteria and fungi in com- fine chemicals, pharmaceuticals and their building blocks, petitive large-scale bioprocesses stems from their simple * Corresponding author; E-mail: [email protected] Abbreviations: CYP: cytochrome P450; EDA: ethylenediamine; e.e.: enantiomeric excess; FDH: formate dehydrogenase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GDH: glutamate dehydrogenase; GlcNAc: N-acetyl-D-glucosamine; HbHNL: hydroxynitrile lyase from Hevea brasiliensis; HLADH: horse liver alcohol dehydrogenase; HNLs: hydroxynitrile lyases; LDH: lactate dehydrogenase; LuHNL: hydroxynitrile lyase from Linum usitatissimum; MDL: mandelonitrile lyase; MeHNL: hydroxynitrile lyase from Manihot esculenta; Neu5Ac: N-acetylneuraminic acid; PaHNL: hydroxynitrile lyase from Prunus amygdalus; PDH: phenylalanine dehydrogenase; PLE: pig liver esterase; PPL: porcine pancreatic lipase; rPLE: recombinant PLE isoenzyme; SbHNL: hydroxynitrile lyase from Sorghum bicolor; YADH: yeast alcohol dehydrogenase 238 Z. LIU et al.: Enzymes from Higher Eukaryotes for Industrial Biocatalysis, Food Technol. Biotechnol. 42 (4) 237–249 (2004) and quick genetic manipulation (5) and also the simple genic P450s synthesize steroids and other substances access to large amounts of native enzymes. For compari- necessary for the maintenance of cell wall integrity and son, higher eukaryotes provide interesting enzymes (6–8), cellular differentiation. The majority of enzymes of the but they usually need to be isolated and purified or human xenobiotic group are expressed in liver micro- cloned and over-expressed in suitable hosts in order to somes. They perform a number of physiological func- obtain sufficient quantities for biocatalytic applications. tions but their primary role is in the metabolism of xeno- In the past years, the use of synthetic host-adopted genes biotics. A large number of potential drug candidates fail and codon-optimized Escherichia coli strains and the de- in later stages of drug development because they are velopment of highly successful eukaryotic expression readily degraded or because they interfere with the me- systems, such as the methylotrophic yeasts Pichia pasto- tabolism of other therapeutics by human cytochrome P450 ris and Hansenula polymorpha, have enabled the produc- (CYP) isozymes. An early assessment of drug/drug in- tion of large quantities of eukaryotic enzymes within a teractions and isozyme-specific CYP450 induction or in- short time (9). hibition is an essential part of the modern drug discov- An increasing experience in molecular modelling ery process (20). (10,11), which rationalizes molecule and biocatalyst en- Among these CYP isozymes, the CYP3A enzyme fa- gineering, as well as recent progress in high-throughput mily is responsible for the hepatic metabolism of approxi- technologies for the expression and engineering of eu- mately 60 % of currently available pharmaceutical agents karyotic proteins provide great potential to extend in- (such as Mephenytoin®, Nevirapine®, Nifedipine®, Nicar- dustrial applications of eukaryotic enzymes (12). Directed dipine®, Cyclophosphamide®, Clotrimazole®, Erythromy- evolution of enzymes in the test tube by repeated cycles cin® and Fluconazole®)(21,22). About 25 % of all drugs of random mutagenesis or recombination followed by used today are substrates for the CYP2D6 isozyme (23) screening and selection provides a powerful tool if and many others inhibit or induce its activity. Approxi- structural or mechanistic information is not available mately 15 % of all drugs used today are metabolized by and if efficient screening technology exists (13). In addi- the CYP1A2 isozyme (23). tion, this technology gives access to improved enzymes Industrial application of human P450s evolves into due to mutations that could not be predicted based on two different directions: (i) the production of active knowledge from static enzyme models. pharmaceutical intermediates, and (ii) the simple and Enzymes from higher eukaryotes have been tradi- fast production of metabolites in mg-scale for drug de- tionally used in the food industry, for example, as food velopment. additives, in fruit processing, in wine brewing and as Human cytochrome P450s have been expressed in pharmaceutical additives. Examples include the extensive different systems such as mammalian cells (24,25), insect use of papain, bromelain, chymosin, ficin, lipoxygenase cells (26), yeasts (27–29) and bacteria such as Escherichia or pepsin (14). However, most of these processes were coli (30,31). E. coli expression systems have the advan- already developed in the 1980s (15–17) and therefore tages of being easier and less expensive to operate and cannot be considered as recent applications, although the of yielding higher quantities of recombinant proteins. products are still widely used. Folding and solubility problems are usually solved by Oxidoreductases (E.C. 1), hydrolases (E.C. 3), lyases synthesis of optimized genes and N-terminal fusions (E.C. 4) and isomerases (E.C. 5) provide the vast major- with other protein sequences that allow correct targeting ity of examples of higher eukaryotic enzymes for indus- or increase protein solubility. Dramatic improvement in trial applications; there are no commercial processes re- the levels of reconstitution of activity of human CYP450 ported for plant or animal enzymes from other catalytic in Escherichia coli was obtained by coexpression of P450 groups. In this review, the main focus is on implemented reductase (32,33). Recently, a human mitochondrial cyto- biocatalytic applications of eukaryotic enzymes in in- chrome P450 (P450 aldosterone synthase) was function- dustrial processes for the production of fine chemicals, ally expressed in the fission yeast Schizosaccharomyces as well as some recent promising developments at pilot pombe. No co-expression of P450 reductase was needed scale and for the preparative synthesis of compounds for efficient substrate conversion by intact fission yeast for industrial drug development processes. cells. Expression was much higher in fission yeast mi- crosomes than in Saccharomyces cerevisiae and the trans- formed yeast showed inducible activity for the in vivo Production of Fine Chemicals and Metabolites conversion of considerable amounts of 11-deoxycortisol with E.C. 1 – Oxidoreductases to cortisol. Furthermore, 11-deoxycorticosterone could be converted almost entirely to corticosterone, with small Mammalian cytochrome P450 amounts of 18-hydroxycorticosterone and aldosterone as Mammalian cytochrome P450 (CYP) monooxygena- by-products (29). This study can be regarded as a signif- ses comprise a superfamily of hemoproteins with extra- icant step towards simple and efficient over-expression ordinary catalytic versatility. They catalyze the metabo- and characterization of human P450s and represents lism of a wide variety of endogenous and exogenous considerable progress concerning their possible applica- compounds including environmental contaminants, hor- tions in fermentative production processes. mones, therapeutic drugs and (pro)carcinogens (18–20). The co-expression of human CYP3A4 and human The human CYP enzyme system is divided into two NADPH-cytochrome P450 oxidoreductase in insect cells large
Load more

Recommended publications
  • Bioprospecting for Hydroxynitrile Lyases by Blue Native PAGE Coupled HCN Detection
    Send Orders for Reprints to [email protected] Current Biotechnology, 2015, 4, 111-117 111 Bioprospecting for Hydroxynitrile Lyases by Blue Native PAGE Coupled HCN Detection Elisa Lanfranchi1, Eva-Maria Köhler1, Barbara Darnhofer1,2,3, Kerstin Steiner1, Ruth Birner-Gruenberger1,2,3, Anton Glieder1,4 and Margit Winkler*,1 1ACIB GmbH, Graz, Austria; 2Institute for Pathology, Medical University of Graz, Graz, Austria; 3Omics Center Graz, BioTechMed, Graz, Austria; 4Institute of Molecular Biotechnology, Graz University of Technology, NAWI Graz, Graz, Austria Abstract: Hydroxynitrile lyase enzymes (HNLs) catalyze the stereoselective addition of HCN to carbonyl compounds to give valuable chiral hydroxynitriles. The discovery of new sources of HNL activity has been reported several times as the result of extensive screening of diverse plants for cyanogenic activity. Herein we report a two step-method that allows estimation of not only the native size of the active HNL enzyme but also its substrate specificity. Specifically, crude protein extracts from plant tissue are first subjected to blue native-PAGE. The resulting gel is then directly used for an activity assay in which the formation of hydrocyanic acid (HCN) is detected upon the cyanogenesis reaction of any cyanohydrin catalyzed by the enzyme of interest. The same gel may be used with different substrates, thus exploring the enzyme’s substrate scope already on the screening level. In combination with mass spectrometry, sequence information can be retrieved, which is demonstrated
    [Show full text]
  • The HOTHEAD Protein: Assessing Enzymatic Activity Using Computational and Recombinant Protein Expression Approaches
    The HOTHEAD Protein: Assessing Enzymatic Activity using Computational and Recombinant Protein Expression Approaches By Eric Le Dreff-Kerwin A thesis Presented to the University of Waterloo In fulfillment of the Thesis requirement for the degree of Master of Science In Biology Waterloo, Ontario, Canada, 2019 © Eric Le Dreff-Kerwin 2019 Author’s Declaration I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. ii Abstract In Arabidopsis thaliana, a number of genes regulating cuticle synthesis have been identified by virtue of organ fusion phenotype. One such gene, HOTHEAD (HTH) was among those originally identified by this phenotype but its exact role in cuticle formation has proven challenging to determine. Previous bioinformatic work has identified that the HTH protein is a member of the GMC oxidoreductase family, and shares peptide sequence identity with a mandelonitrile lyase and an alcohol dehydrogenase that are within the same protein family. This thesis work investigated the potential enzymatic function of HTH by comparing a structural model to two structural analogs. The structure model of HTH, as determined in this study, shows that HTH shares certain conserved features of GMC proteins. The aim of this research also included isolating a recombinantly expressed HTH protein from Escherichia coli and initial work in Pichia pastoris. Protein isolation attempts in Escherichia coli failed to yield active HTH protein, potentially due to the lack of post-translational modifications.
    [Show full text]
  • Crystallization and Preliminary X-Ray Diffraction Studies of Mandelonitrile Lyase from Almonds
    PROTEINS: Structure, Function, and Genetics 19:343-347 (1994) Crystallization and Preliminary X-Ray Diffraction Studies of Mandelonitrile Lyase From Almonds Hanspeter Lauble,' Kirsten Muller,' Hermann Schindelin? Siegfried Forster,' and Franz Effenberger' 'Institut fur Organische Chemie und Isotopenforschung, Uniuersitat Stuttgart, 0-70569 Stuttgart, Germany and 'Institut fur Kristallographie, Freie Universitat Berlin, 0-14195 Berlin, Germany ABSTRACT Single crystals of three differ- alyzing the dissociation of mandelonitrile into ben- ent isoenzymes of (R)-( +) mandelonitrile lyase zaldehyde and HCN.1° The protein is a single poly- (hydroxynitrile lyase) from almonds (Prunus peptide (M, 75,000) containing a FAD cofactor and is amygdalus) have been obtained by hanging heavily N-glycosylated with oligomannose units (H. drop vapor diffusion using polyethylene glycol Wajand, unpublished results). The amino-acid se- 4000 and isopropanol as co-precipitants. The quence of 12 tryptic peptides derived from MNL-A crystals belong to the monoclinic space group comprises 177 residues of the entire sequence (H. P2, with unit cell parameters a = 69.9, b = 95.1, Wajand, unpublished report). Recently the primary c = 95.6 A, and p = 118.5'. A complete set of structure of the black cherry (Prunus serotina) MNL diffraction data has been collected to 2.6 A res- has been deduced from its cDNA. l2 The sequence of olution on native crystals of isoenzyme 111. the tryptic peptides of MNL-A has been aligned with 0 1994 Wiley-Liss, Inc. respect to the black cherry
    [Show full text]
  • Chandran Et Al. Supporting Info.Pdf
    Supporting Information (SI) Appendix Part 1. Impact of tissue preparation, LMD, and RNA amplification on array output. p. 2 Text S1: Detailed Experimental Design and Methods Figure S1A: Correlation analysis indicates tissue preparation has minimal impact on ATH1 array output. Figure S1B: Correlation analysis indicates RNA degradation does not significantly impact array output. Figure S1C: Correlation analysis indicates two-round amplification does not significantly impact array output. Figure S1D: Independent biological replicates of LMD samples are highly correlated. Figure S1E: Validation of LMD array expression by qPCR. Table S1: Tissue preparation-associated genes Part 2. Analysis of LMD and parallel whole leaf array data. p. 13 Table S2A: Known PM-impacted genes enriched in LMD dataset Table S2B: Dataset of LMD and whole leaf genes with PM-altered expression Table S2C: LMD PM MapMan Results and Bins Table S2D: ics1 vs. WT LMD PM MapMan Results and Bins Table S2E: Infection site-specific changes for redox and calcium categories Table S2F: cis-acting regulatory element motif analysis Part 3. Process network construction p. 149 3A. Photosynthesis 3B. Cold/dehydration response Part 4. Powdery mildew infection of WT and myb3r4 mutants p. 173 Text S4: Detailed Experimental Design and Methods (supplement to manuscript) Figure S4A. Uninfected 4 week old WT and myb3r4 plants Figure S4B. myb3r4 mutants exhibit reduced visible PM growth and reproduction Figure S4C. PM-infected WT and myb3r4 mutants do not exhibit cell death Figure S4D. Endoreduplication occurs at site of PM infection not distal to infection Figure S4E. Ploidy correlates with nuclear size. Part 1. Impact of tissue preparation, LMD, and RNA amplification on array output.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • A New (R)-Hydroxynitrile Lyase from Prunus Mume: Asymmetric Synthesis of Cyanohydrins
    Tetrahedron 61 (2005) 10908–10916 A new (R)-hydroxynitrile lyase from Prunus mume: asymmetric synthesis of cyanohydrins Samik Nanda, Yasuo Kato and Yasuhisa Asano* Biotechnology Research Center, Toyama Prefectural University, 5180 Kurokawa, Kosugi, Toyama 939-0398, Japan Received 8 August 2005; revised 31 August 2005; accepted 31 August 2005 Available online 23 September 2005 Abstract—A new hydroxynitrile lyase (HNL) was isolated from the seed of Japanese apricot (Prunus mume). The enzyme has similar properties with HNL isolated from other Prunus species and is FAD containing enzyme. It accepts a large number of unnatural substrates (benzaldehyde and its variant) for the addition of HCN to produce the corresponding cyanohydrins in excellent optical and chemical yields. A new HPLC based enantioselective assay technique was developed for the enzyme, which promotes the addition of KCN to benzaldehyde in a buffered solution (pHZ4.5). q 2005 Elsevier Ltd. All rights reserved. 1. Introduction has proved not sufficient simply to screen for the presence of carbonyl compounds or HCN, since the breakdown of Hydroxynitrile lyases (HNLs) are widely distributed in cyanohydrins may be catalyzed by enzymes other than nature and believed mainly to be a plant enzyme. There are HNLs: instead, the catalysis of cyanohydrin formation is a four classes of HNL reported in the literature till now,1 more reliable indicator of the presence of a HNL.6 among them mandelonitrile lyase (EC 4.1.2.10) has been extensively studied in the area of enzymology and organic Optically active cyanohydrins are excellent building blocks synthesis. Hydroxynitrile lyases (HNLs) are one of the key for the total synthesis of several biologically active natural 7 enzymes in cyanogenic plants,2 catalyzing the final step in products.
    [Show full text]
  • WO 2016/020528 Al 11 February 2016 (11.02.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/020528 Al 11 February 2016 (11.02.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 9/88 (2006.0 1) C12P 13/00 (2006.0 1) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP20 15/068262 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 7 August 2015 (07.08.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 14180247.0 7 August 2014 (07.08.2014) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: ACIB GMBH [AT/AT]; Petersgasse 14, A- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 8010 Graz (AT).
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced hx>m the microfilm master. UMI films the text directly fi’om the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter 6ce, while others may be fi-om any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing fi’om left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/521-0600 CHARACTERIZATION, PURIFICATION, AND MOLECULAR CLONING OF HYDROXYNITRILE LYASE FROM CASSAVA (MANIHOT ESCULENTA CRANTZ ) DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Wanda Lynn Broyles White, B.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Aureliano Bombarely, Boyce Thompson Institute LycoCyc: Solanum lycopersicum Cellular Overview Lukas Mueller, Boyce Thompson Institute a xenobiotic a xenobiotic a xenobiotic a xenobiotic + a xenobiotic a xenobiotic H phosphonate 2+ an a xenobiotic a xenobiotic ABC a xenobiotic a xenobiotic a xenobiotic ABC a xenobiotic Cd a xenobiotic a xenobiotic a xenobiotic ABC a xenobiotic ABC a xenobiotic a xenobiotic a xenobiotic oligopeptide a xenobiotic a xenobiotic Cd 2+ a xenobiotic sucrose a xenobiotic transporter transporter transporter transporter sucrose H + a xenobiotic a xenobiotic C family C family C family C family a xenobiotic a xenobiotic ABC a xenobiotic a xenobiotic a xenobiotic a xenobiotic a xenobiotic Macrolide ABC a xenobiotic sucrose H(+)-ATPase H + member 4/ member 8/ a xenobiotic member 10/ member 10/ Cu 2+ H + transporter ABC export ATP- ABC transporter 4//H(\+)- ABC /Multidrug ABC ABC ABC /Multidrug ABC Cadmium- ABC ABC ABC /Multidrug ABC /Multidrug ABC ABC ABC Sucrose C family transporter ABC binding/ transporter B family Sucrose transporting transporter ABC resistance transporter transporter transporter resistance transporter transporting Cadmium/zinc- ABC transporter transporter transporter resistance transporter resistance transporter transporter transporter transport ABC transporter member 2/ I family transporter permease B family member transport Sucrose ATP synthase atpase plant/ MATE efflux ABC C family transporter protein ABC C family C family C family protein ABC C family ATPase// transporting transporter
    [Show full text]
  • EUROPEAN PATENT OFFICE, VIENNA Thousand Oaks, CA 91320 (US) SUB-OFFICE
    Europäisches Patentamt *EP001033405A2* (19) European Patent Office Office européen des brevets (11) EP 1 033 405 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C12N 15/29, C12N 15/82, 06.09.2000 Bulletin 2000/36 C07K 14/415, C12Q 1/68, A01H 5/00 (21) Application number: 00301439.6 (22) Date of filing: 25.02.2000 (84) Designated Contracting States: • Brover, Vyacheslav AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Calabasas, CA 91302 (US) MC NL PT SE • Chen, Xianfeng Designated Extension States: Los Angeles, CA 90025 (US) AL LT LV MK RO SI • Subramanian, Gopalakrishnan Moorpark, CA 93021 (US) (30) Priority: 25.02.1999 US 121825 P • Troukhan, Maxim E. 27.07.1999 US 145918 P South Pasadena, CA 91030 (US) 28.07.1999 US 145951 P • Zheng, Liansheng 02.08.1999 US 146388 P Creve Coeur, MO 63141 (US) 02.08.1999 US 146389 P • Dumas, J. 02.08.1999 US 146386 P , (US) 03.08.1999 US 147038 P 04.08.1999 US 147302 P (74) Representative: 04.08.1999 US 147204 P Bannerman, David Gardner et al More priorities on the following pages Withers & Rogers, Goldings House, (83) Declaration under Rule 28(4) EPC (expert 2 Hays Lane solution) London SE1 2HW (GB) (71) Applicant: Ceres Incorporated Remarks: Malibu, CA 90265 (US) THE COMPLETE DOCUMENT INCLUDING REFERENCE TABLES AND THE SEQUENCE (72) Inventors: LISTING IS AVAILABLE ON CD-ROM FROM THE • Alexandrov, Nickolai EUROPEAN PATENT OFFICE, VIENNA Thousand Oaks, CA 91320 (US) SUB-OFFICE.
    [Show full text]